Aeglea Bio Therapeutics (NASDAQ:AGLE) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday, Zacks.com reports.

According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “

Several other equities research analysts have also issued reports on AGLE. ValuEngine upgraded Aeglea Bio Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. BidaskClub upgraded Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, September 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $14.33.

NASDAQ AGLE traded up $0.03 during trading on Monday, reaching $7.93. 2,346 shares of the company’s stock were exchanged, compared to its average volume of 34,699. Aeglea Bio Therapeutics has a fifty-two week low of $5.99 and a fifty-two week high of $9.45. The firm has a market capitalization of $233.04 million, a PE ratio of -3.75 and a beta of 1.07. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $7.73 and its 200-day simple moving average is $7.37.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.12). Equities analysts forecast that Aeglea Bio Therapeutics will post -2.51 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new position in Aeglea Bio Therapeutics in the 2nd quarter worth approximately $27,000. Bank of Montreal Can increased its position in Aeglea Bio Therapeutics by 116.5% in the 2nd quarter. Bank of Montreal Can now owns 6,749 shares of the biotechnology company’s stock worth $47,000 after buying an additional 3,631 shares during the period. Commonwealth Equity Services LLC bought a new position in Aeglea Bio Therapeutics in the 2nd quarter worth approximately $68,000. Susquehanna International Group LLP bought a new position in Aeglea Bio Therapeutics in the 2nd quarter worth approximately $83,000. Finally, A.R.T. Advisors LLC bought a new position in Aeglea Bio Therapeutics in the 2nd quarter worth approximately $143,000. Institutional investors and hedge funds own 69.04% of the company’s stock.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

See Also: Overbought

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.